Blar i forfatter "Nordengen, Kaja"

Viser treff 1-5 av 5

    • Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease 

      Kirsebom, Bjørn-Eivind; Nordengen, Kaja; Selnes, Per; Waterloo, Knut; Torsetnes, Silje Bøen; Gísladóttir, Berglind; Brix, Britta; Vanmechelen, Eugeen; Bråthen, Geir; Hessen, Erik; Aarsland, Dag; Fladby, Tormod (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-11-10)
      <i>Introduction</i>: The cerebrospinal fluid neurogranin (Ng)/β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) ratio may reflect synaptic affection resulting from reduced beta-amyloid (Aβ) clearance. We hypothesize that increased Ng/BACE1 ratio predicts the earliest cognitive decline in Alzheimer’s disease.<p> <p><i>Methods</i>: We compared Ng/BACE1 levels between cases with subjective ...

    • Glial activation and inflammation along the Alzheimer's disease continuum 

      Nordengen, Kaja; Kirsebom, Bjørn-Eivind; Henjum, Kristi; Selnes, Per; Gisladottir, Berglind; Wettergreen, Marianne; Torsetnes, Silje Bøen; Grøntvedt, Gøril Rolfseng; Waterloo, Knut; Aarsland, Dag; Nilsson, Lars; Fladby, Tormod (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-02-21)
      <p><i>Background - </i>Neuronal and glial cell interaction is essential for synaptic homeostasis and may be affected in Alzheimer’s disease (AD). We measured cerebrospinal fluid (CSF) neuronal and glia markers along the AD continuum, to reveal putative protective or harmful stage-dependent patterns of activation. <p><i>Methods - </i>We included healthy controls (<i>n</i> = 36) and Aβ-positive (Aβ+) ...

    • Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease 

      Nordengen, Kaja; Kirsebom, Bjørn-Eivind Seljelid; Richter, Grit; Pålhaugen, Lene; Gisladottir, Berglind; Siafarikas, Nikias Ioannis; Nakling, Arne Exner; Rongve, Arvid; Bråthen, Geir; Grøntvedt, Gøril Rolfseng; Gonzalez, Fernando; Waterloo, Knut; Sharma, Kulbhushan; Karikari, Thomas; Vromen, Eleonora M.; Tijms, Betty M.; Visser, Pieter J.; Selnes, Per; Kramberger, Milicia G.; Winblad, Bengt; Blennow, Kaj; Fladby, Tormod (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-12-13)
      Background - Brain innate immune activation is associated with Alzheimer’s disease (AD), but degrees of activation may vary between disease stages. Thus, brain innate immune activation must be assessed in longitudinal clinical studies that include biomarker negative healthy controls and cases with established AD pathology. Here, we employ longitudinally sampled cerebrospinal fluid (CSF) core AD, ...

    • Medial Temporal Lobe Atrophy in Predementia Alzheimer's Disease: A Longitudinal Multi-Site Study Comparing Staging and A/T/N in a Clinical Research Cohort 

      Jarholm, Jonas Alexander; Bjørnerud, Atle; Dalaker, Turi Olene; Akhavi, Mehdi Sadat; Kirsebom, Bjørn-Eivind; Pålhaugen, Lene; Nordengen, Kaja; Grøntvedt, Gøril Rolfseng; Nakling, Arne Exner; Kalheim, Lisa Flem; Almdahl, Ina Selseth; Teceläo, Sandra Raquel Ramos; Fladby, Tormod; Selnes, Per (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-06-27)
      Background: Atrophy of the medial temporal lobe (MTL) is a biological characteristic of Alzheimer’s disease (AD) and can be measured by segmentation of magnetic resonance images (MRI). Objective: To assess the clinical utility of automated volumetry in a cognitively well-defined and biomarker-classified multi-center longitudinal predementia cohort. <p>Methods: We used Automatic Segmentation of ...

    • Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer's disease patients 

      Kirsebom, Bjørn-Eivind; Richter, Grit; Nordengen, Kaja; Aarsland, Dag; Bråthen, Geir; Tijms, Betty M; Visser, Pieter Jelle; Nilsson, Johanna; Selnes, Per; Kramberger, Milica G.; Winblad, Bengt; Waterloo, Knut; Gísladóttir, Berglind; Blennow, Kaj; Fladby, Tormod (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-09-24)
      Cerebrospinal fluid (CSF) β-site amyloid precursor protein cleaving enzyme 1 (BACE1), neurogranin and the neurogranin/BACE1 ratio are proposed markers for Alzheimer’s disease. BACE1 is also a drug target. However, CSF levels may differ between early-stage amyloid plaque formation (A) and later stage downstream tau-tangle pathology (T) and neurodegeneration (N) and may be expressed as an A/T/N stage ...